We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+8.36%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$184M
Cap. Flow
+$269M
Cap. Flow %
24.82%
Top 10 Hldgs %
42.57%
Holding
126
New
25
Increased
29
Reduced
26
Closed
35

Top Buys

Rank Stock Value
1
TMCI icon
Treace Medical Concepts
TMCI
+$34.9M
2
TGTX icon
TG Therapeutics
TGTX
+$34.1M
3
GSK icon
GSK
GSK
+$33.5M
4
PODD icon
Insulet
PODD
+$28.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$16.8M

Top Sells

Rank Stock Value
1
CRL icon
Charles River Laboratories
CRL
+$23.3M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$13.7M
3
ACLX
Arcellx
ACLX
+$12.3M
4
CVS icon
CVS Health
CVS
+$11.5M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.95M

Sector Composition

Rank Sector Weight
1 Healthcare 90.02%
2 Consumer Staples 1.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
51
Insmed
INSM
$28.7B
$5.5M 0.51%
+218,000
New +$4.99M
ETNB
52
DELISTED
89bio
ETNB
$5.34M 0.49%
346,033
+119,533
+53% +$2.01M
URGN icon
53
UroGen Pharma
URGN
$2.22B
$5.21M 0.48%
+372,000
New +$5.97M
ACAD icon
54
Acadia Pharmaceuticals
ACAD
$4.9B
$5.1M 0.47%
244,627
+178,627
+271% +$4.85M
THTX
55
DELISTED
Theratechnologies
THTX
$5.01M 0.46%
+2,331,376
New +$4.99M
CCCC icon
56
C4 Therapeutics
CCCC
$402M
$5.01M 0.46%
2,692,020
– –
CSTL icon
57
Castle Biosciences
CSTL
$931M
$4.79M 0.44%
+283,500
New +$4.96M
NSPR icon
58
InspireMD
NSPR
$33.8M
$4.51M 0.42%
1,378,128
– –
TARS icon
59
Tarsus Pharmaceuticals
TARS
$2.85B
$4.44M 0.41%
+250,000
New +$4.42M
MCRB icon
60
Seres Therapeutics
MCRB
$47.9M
$4.33M 0.4%
91,049
-11,250
-11% -$859K
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$5.74B
$3.25M 0.3%
103,000
-73,000
-41% -$2M
APLT
62
DELISTED
Applied Therapeutics
APLT
$2.97M 0.27%
+1,192,626
New +$1.97M
BHVN icon
63
Biohaven
BHVN
$2.17B
$2.96M 0.27%
+113,800
New +$2.37M
WGS icon
64
GeneDx Holdings
WGS
$2.08B
$2.84M 0.26%
781,396
+70,000
+10% +$384K
KNSA icon
65
Kiniksa Pharmaceuticals
KNSA
$5.97B
$2.73M 0.25%
157,349
-362,291
-70% -$6.1M
NTRA icon
66
Natera
NTRA
$38B
$2.72M 0.25%
61,377
-107,423
-64% -$5.48M
DSGN icon
67
Design Therapeutics
DSGN
$862M
$2.42M 0.22%
+1,025,000
New +$4.78M
LYRA
68
DELISTED
LYRA THERAPEUTICS INC
LYRA
$2.32M 0.21%
11,848
– –
PRAX icon
69
Praxis Precision Medicines
PRAX
$10.3B
$1.97M 0.18%
76,667
-63,333
-45% -$1.2M
XENE icon
70
Xenon Pharmaceuticals
XENE
$6.24B
$1.78M 0.16%
52,000
-14,000
-21% -$524K
SNDX icon
71
Syndax Pharmaceuticals
SNDX
$1.76B
$1.74M 0.16%
119,500
-93,100
-44% -$1.76M
WHWK
72
Whitehawk Therapeutics
WHWK
$232M
$1.61M 0.15%
333,227
– –
FDMT icon
73
4D Molecular Therapeutics
FDMT
$552M
$1.58M 0.15%
123,748
-95,400
-44% -$1.6M
ALKS icon
74
Alkermes
ALKS
$8.11B
$1.52M 0.14%
54,400
-140,000
-72% -$4.1M
VKTX icon
75
Viking Therapeutics
VKTX
$3.88B
$1.35M 0.12%
122,200
-214,500
-64% -$3.07M
1 2
3
4 5

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Soleus Capital Management held 126 positions worth $1.08B, up 20% from $900M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Soleus Capital Management deployed $269M of net new capital in Q3 2023, opening 25 new positions and adding to 29 existing holdings. Its largest new stake was Treace Medical Concepts: 1,907,823 shares worth $25M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Charles River Laboratories, an estimated $23.3M trimmed.

  • Soleus Capital Management's largest Q3 2023 buy was Treace Medical Concepts: 1,907,823 shares worth $25M.
  • Soleus Capital Management added most to TG Therapeutics in Q3 2023, an estimated $34.1M increase.
  • Soleus Capital Management's biggest Q3 2023 reduction was Charles River Laboratories, cutting an estimated $23.3M.
  • Soleus Capital Management fully exited Seagen Inc. Common Stock in Q3 2023, selling an estimated $13.7M.
  • Soleus Capital Management's ten largest holdings make up 43% of its $1.08B portfolio in Q3 2023.
  • Soleus Capital Management opened 25 new positions and closed 35 in Q3 2023.
  • Soleus Capital Management's portfolio value rose 20% quarter-over-quarter to $1.08B.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.